These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35341688)

  • 1. The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.
    Saunders H; Pham B; Loong D; Mishra S; Ashoor HM; Antony J; Darvesh N; Bains SK; Jamieson M; Plett D; Trivedi S; Yu CH; Straus SE; Tricco AC; Isaranuwatchai W
    Value Health; 2022 Jul; 25(7):1235-1252. PubMed ID: 35341688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis.
    Tricco AC; Ashoor HM; Antony J; Bouck Z; Rodrigues M; Pham B; Khan PA; Nincic V; Darvesh N; Yazdi F; Ghassemi M; Ivory JD; Veroniki AA; Yu CH; Moja L; Straus SE
    J Gen Intern Med; 2021 Aug; 36(8):2414-2426. PubMed ID: 33742305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.
    Tieu C; Lucas EJ; DePaola M; Rosman L; Alexander GC
    PLoS One; 2018; 13(4):e0195012. PubMed ID: 29668697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars and Novel Insulins.
    Ampudia-Blasco FJ
    Am J Ther; 2020; 27(1):e52-e61. PubMed ID: 31764128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar vs originator insulins: Systematic review and meta-analysis.
    Yamada T; Kamata R; Ishinohachi K; Shojima N; Ananiadou S; Nom H; Yamauchi T; Kadowaki T
    Diabetes Obes Metab; 2018 Jul; 20(7):1787-1792. PubMed ID: 29536603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, effectiveness, and cost of long-acting versus intermediate-acting insulin for type 1 diabetes: protocol for a systematic review and network meta-analysis.
    Tricco AC; Ashoor HM; Soobiah C; Hemmelgarn B; Moher D; Hutton B; Yu CH; Majumdar SR; Straus SE
    Syst Rev; 2013 Sep; 2():73. PubMed ID: 24020869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
    Godman B; Wladysiuk M; McTaggart S; Kurdi A; Allocati E; Jakovljevic M; Kalemeera F; Hoxha I; Nachtnebel A; Sauermann R; Hinteregger M; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Slabý J; Nejezchlebova R; Krulichová IS; Laius O; Selke G; Langner I; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuolienė K; Gulbinovič J; Bonanno PV; Rutkowski J; Ingeberg S; Melien Ø; Mardare I; Fürst J; MacBride-Stewart S; Holmes C; Pontes C; Zara C; Pedrola MT; Hoffmann M; Kourafalos V; Pisana A; Banzi R; Campbell S; Wettermark B
    Biomed Res Int; 2021; 2021():9996193. PubMed ID: 34676266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2018 Feb; 20(S1):S55-S70. PubMed ID: 29437477
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of insulin analogues for diabetes mellitus.
    Cameron CG; Bennett HA
    CMAJ; 2009 Feb; 180(4):400-7. PubMed ID: 19221353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction of biosimilar insulins in Europe.
    Davies M; Dahl D; Heise T; Kiljanski J; Mathieu C
    Diabet Med; 2017 Oct; 34(10):1340-1353. PubMed ID: 28608570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus.
    Shafie AA; Ng CH; Tan YP; Chaiyakunapruk N
    Pharmacoeconomics; 2017 Feb; 35(2):141-162. PubMed ID: 27752998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.
    Godman B; Haque M; Leong T; Allocati E; Kumar S; Islam S; Charan J; Akter F; Kurdi A; Vassalo C; Bakar MA; Rahim SA; Sultana N; Deeba F; Khan MAH; Alam ABMM; Jahan I; Kamal ZM; Hasin H; Munzur-E-Murshid ; Nahar S; Haque M; Dutta S; Abhayanand JP; Kaur RJ; Rwegerera GM; do Nascimento RCRM; Dias Godói IP; Irfan M; Amu AA; Matowa P; Acolatse J; Incoom R; Sefah IA; Acharya J; Opanga S; Njeri LW; Kimonge D; Kwon HY; Bae S; Khuan KKP; Abubakar AR; Sani IH; Khan TA; Hussain S; Saleem Z; Malande OO; Piloya-Were T; Gambogi R; Hernandez Ortiz C; Alutuli L; Kalungia AC; Hoxha I; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Laius O; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuoliene K; Gulbinovič J; Wladysiuk M; Rutkowski J; Mardare I; Fürst J; McTaggart S; MacBride-Stewart S; Pontes C; Zara C; Tagoe ET; Banzi R; Wale J; Jakovljevic M
    Front Public Health; 2021; 9():671961. PubMed ID: 34249838
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
    Russel-Szymczyk M; Valov V; Savova A; Manova M
    BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
    Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
    Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging Clinical Pharmacology Data to Assess Biosimilarity and Interchangeability of Insulin Products.
    Vaidyanathan J; Wang YC; Tran D; Seo SK
    Clin Pharmacol Ther; 2023 Apr; 113(4):794-802. PubMed ID: 36052570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2017 Feb; 19(S1):S42-S58. PubMed ID: 28192016
    [No Abstract]   [Full Text] [Related]  

  • 18. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.
    Fullerton B; Siebenhofer A; Jeitler K; Horvath K; Semlitsch T; Berghold A; Plank J; Pieber TR; Gerlach FM
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD012161. PubMed ID: 27362975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2016 Feb; 18 Suppl 1():S43-55. PubMed ID: 26836429
    [No Abstract]   [Full Text] [Related]  

  • 20. Biosimilar insulins: guidance for data interpretation by clinicians and users.
    Heinemann L; Home PD; Hompesch M
    Diabetes Obes Metab; 2015 Oct; 17(10):911-8. PubMed ID: 25974131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.